• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Boston Scientific Announces Results for Second Quarter 2024

    7/24/24 6:30:00 AM ET
    $BSX
    $SILK
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $BSX alert in real time by email

    MARLBOROUGH, Mass., July 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis and 14.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $324 million or $0.22 per share (EPS), compared to $261 million or $0.18 per share a year ago, and achieved adjusted3 EPS of $0.62 for the period, compared to $0.53 a year ago.

    Boston Scientific Corporation (PRNewsFoto/Boston Scientific Corporation) (PRNewsFoto/Boston Scientific Corporation)

    "We delivered a quarter marked by exceptional performance, reflecting our global team's relentless pursuit of innovation that is supported by strong clinical evidence and investments aligned with our strategy of category leadership," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "We remain excited about our plans for the future, and I am incredibly grateful for the commitment and winning spirit of our employees around the world."

    Second quarter financial results and recent developments:

    • Reported net sales of $4.120 billion, representing an increase of 14.5 percent on a reported basis, compared to the company's guidance range of 10.5 to 12.5 percent; 16.1 percent on an operational basis; and 14.7 percent on an organic basis, compared to the company's guidance range of 10 to 12 percent, all compared to the prior year period.

        
    • Reported GAAP net income attributable to Boston Scientific common stockholders of $0.22 per share, compared to the company's guidance range of $0.35 to $0.37 per share, and achieved adjusted EPS of $0.62 per share, compared to the guidance range of $0.57 to $0.59 per share.

        
    • Achieved the following net sales growth in each reportable segment, compared to the prior year period:
      • MedSurg: 9.0 percent reported, 10.1 percent operational and 7.6 percent organic
      • Cardiovascular: 17.8 percent reported, 19.7 percent operational and 19.0 percent organic

          
    • Achieved the following net sales growth in each region, compared to the prior year period:
      • United States (U.S.): 16.9 percent reported and operational
      • Europe, Middle East and Africa (EMEA): 13.7 percent reported and 16.1 percent operational
      • Asia-Pacific (APAC): 7.0 percent reported and 13.2 percent operational
      • Latin America and Canada (LACA): 15.3 percent reported and 15.7 percent operational
      • Emerging Markets4: 14.8 percent reported and 19.3 percent operational

          
    • Received National Medical Products Administration (NMPA) approval in China for the FARAPULSE™ Pulsed Field Ablation (PFA) System.

        
    • Presented the following clinical data at Heart Rhythm 2024:
      • Outcomes from a sub-analysis of the pivotal ADVENT clinical trial of the FARAPULSE PFA System, which demonstrated that treatment with the system resulted in an atrial arrhythmia burden (i.e., the total arrhythmia duration experienced by a patient) of less than 0.1% – a clinically meaningful threshold – in significantly more patients compared to thermal ablation. 
      • Acute outcomes from the global FARADISE registry, which demonstrated favorable 30-day outcomes in more than 1,100 patients treated with the FARAPULSE PFA System, with no deaths or reports of coronary spasm, persistent phrenic nerve palsy, atrioesophageal fistula or pulmonary vein stenosis. 
      • Positive results from the ongoing pivotal MODULAR ATP clinical trial of the Modular CRM (mCRM™) System5 which met all pre-specified six-month safety and effectiveness endpoints. This is the first modular cardiac rhythm management (mCRM) system that consists of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System and the EMPOWER™ Leadless Pacemaker.

          
    • Initiated the U.S. launch of the AGENT™ Drug-Coated Balloon, indicated to treat in-stent restenosis in patients with coronary artery disease, and received NMPA approval for the device in China.

        
    • Announced agreement to acquire Silk Road Medical, Inc., (NASDAQ:SILK) a publicly traded medical technology company that commercialized a platform of products to prevent stroke in patients with carotid artery disease, subject to customary closing conditions.

        
    • Presented outcomes at the 2024 American Society of Pain & Neuroscience meeting from three follow-up studies of patients treated with the Intracept™ Intraosseous Nerve Ablation System, which demonstrated significant improvements in vertebrogenic pain with nearly one-third of patients 100% pain free after five years.

        
    • Elected to the company's board of directors Dr. Cheryl Pegus, former partner at Morgan Health and former executive vice president of Health & Wellness at Walmart.

     

    1. Operational net sales growth excludes the impact of foreign currency fluctuations.

    2. Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales.

    3. Adjusted EPS excludes the impacts of certain charges (credits) which may include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), European Union Medical Device Regulation (EU MDR) implementation costs, debt extinguishment net charges, deferred tax expenses (benefits) and certain discrete tax items.

    4. Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada.

    5. The EMPOWER Leadless Pacemaker is an investigational device and limited by U.S. law to investigational use only. It is not available for sale. Some device references are for informational purposes only and are pending CE Mark. Not available in the European Economic Area.

     

    Net sales for the second quarter by business and region:











    Increase/(Decrease) 





    Three Months Ended

    June 30,



    Reported

    Basis



    Impact of

    Foreign

    Currency

    Fluctuations



    Operational

     Basis



    Impact of

    Recent

    Acquisitions/

    Divestitures



    Organic

    Basis

    (in millions)

    2024

    2023













       Endoscopy

    $            676

    $            631



    7.1 %



    1.3 %



    8.4 %



    (0.5) %



    7.9 %



       Urology

    525

    485



    8.2 %



    0.9 %



    9.1 %



    — %



    9.1 %



       Neuromodulation

    282

    244



    15.5 %



    0.7 %



    16.2 %



    (12.5) %



    3.7 %



    MedSurg

    1,483

    1,360



    9.0 %



    1.0 %



    10.1 %



    (2.5) %



    7.6 %



       Cardiology

    2,047

    1,704



    20.1 %



    1.9 %



    22.0 %



    — %



    22.0 %



       Peripheral Interventions

    590

    535



    10.2 %



    2.1 %



    12.3 %



    (2.8) %



    9.4 %



    Cardiovascular

    2,637

    2,239



    17.8 %



    1.9 %



    19.7 %



    (0.7) %



    19.0 %

    Net Sales

    $       4,120

    $       3,599



    14.5 %



    1.6 %



    16.1 %



    (1.4) %



    14.7 %

     











    Increase/(Decrease)





    Three Months Ended June 30,



    Reported

    Basis



    Impact of

    Foreign

    Currency

    Fluctuations



    Operational

     Basis

    (in millions)

    2024

    2023









    U.S.

    $         2,466

    $         2,110



    16.9 %



    — %



    16.9 %



    EMEA

    822

    723



    13.7 %



    2.5 %



    16.1 %



    APAC

    670

    626



    7.0 %



    6.2 %



    13.2 %



    LACA

    162

    140



    15.3 %



    0.4 %



    15.7 %



    Net Sales

    $       4,120

    $       3,599



    14.5 %



    1.6 %



    16.1 %























    Emerging Markets4

    $         680

    $         592



    14.8 %



    4.6 %



    19.3 %























    Amounts may not add due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.







    Net sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of acquisitions/divestitures are not prepared

    in accordance with U.S. GAAP.

     

    Guidance for Full Year and Third Quarter 2024

    The company estimates net sales growth for the full year 2024, versus the prior year period, to be in range of approximately 13.5 to 14.5 percent on a reported basis, and 13 to 14 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $1.34 to $1.38 and estimates adjusted EPS, excluding certain charges (credits), of $2.38 to $2.42.

    The company estimates net sales growth for the third quarter of 2024, versus the prior year period, to be in a range of approximately 13 to 15 percent on both a reported basis and organic basis. Third quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $0.36 to $0.38 and adjusted EPS, excluding certain charges (credits), of $0.57 to $0.59.

    Conference Call Information

    Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. ET. The company will webcast the call to interested parties through its website: investors.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.

    About Boston Scientific

    Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and connect on LinkedIn and X, formerly Twitter.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales; reported, operational and organic revenue growth rates; reported and adjusted EPS for the third quarter and full year 2024; our financial performance; acquisitions; clinical trials; our business plans and product performance; and new and anticipated product approvals and launches. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

    Risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions; geopolitical events; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release.

    Note: Amounts reported in millions within this press release are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.

    Use of Non-GAAP Financial Information

    A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this press release.

     

    CONTACT:









              Media:

    Emily Anderson



    Investors:

    Jonathan Monson



    617-515-2000 (office)





    508-683-5450 (office)



    Media Relations





    Investor Relations



    Boston Scientific Corporation





    Boston Scientific Corporation



    [email protected]





    [email protected]

     

    BOSTON SCIENTIFIC CORPORATION

    CONSOLIDATED STATEMENTS OF OPERATIONS

    (Unaudited)





    Three Months Ended

    June 30,



    Six Months Ended

    June 30,

    in millions, except per share data

    2024

    2023



    2024

    2023













    Net sales

    $        4,120

    $        3,599



    $        7,977

    $        6,988

    Cost of products sold

    1,270

    1,058



    2,479

    2,098

    Gross profit

    2,850

    2,542



    5,498

    4,891













    Operating expenses:











    Selling, general and administrative expenses

    1,446

    1,354



    2,810

    2,570

    Research and development expenses

    383

    359



    749

    695

    Royalty expense

    9

    12



    19

    23

    Amortization expense

    213

    210



    427

    412

    Intangible asset impairment charges

    276

    57



    276

    57

    Contingent consideration net expense (benefit)

    2

    19



    18

    31

    Restructuring net charges (credits)

    1

    16



    5

    36



    2,330

    2,028



    4,303

    3,825

    Operating income (loss)

    520

    514



    1,195

    1,066













    Other income (expense):











    Interest expense

    (77)

    (70)



    (146)

    (135)

    Other, net

    (23)

    (18)



    (21)

    (61)

    Income (loss) before income taxes

    420

    426



    1,028

    870

    Income tax expense (benefit)

    98

    156



    213

    287

    Net income (loss)

    322

    270



    815

    584

    Preferred stock dividends

    —

    (9)



    —

    (23)

    Net income (loss) attributable to noncontrolling interests

    (2)

    —



    (4)

    —

    Net income (loss) attributable to Boston Scientific

    common stockholders

    $          324

    $          261



    $          819

    $          561













    Net income (loss) per common share - basic

    $         0.22

    $         0.18



    $         0.56

    $         0.39

    Net income (loss) per common share - diluted

    $         0.22

    $         0.18



    $         0.55

    $         0.39













    Weighted-average shares outstanding











    Basic

    1,470.6

    1,446.2



    1,469.5

    1,441.0

    Diluted

    1,484.2

    1,456.2



    1,483.0

    1,451.1

     

    BOSTON SCIENTIFIC CORPORATION

    NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS

    (Unaudited)









    Three Months Ended June 30, 2024



    (in millions, except per share data)

    Gross

    Profit

    Operating

    Expenses

    Operating

    Income

    (Loss)

    Other

    Income

    (Expense)

    Income

    (Loss)

    Before

    Income

    Taxes

    Net

    Income

    (Loss)

    Preferred

    Stock

    Dividends

    Net Income

    (Loss)

    Attributable to

    Noncontrolling

    Interests

    Net Income

    (Loss)

    Attributable to

    Boston

    Scientific

    Common

    Stockholders

    Impact

    per

    Share



    Reported

    $    2,850

    $      2,330

    $        520

    $       (100)

    $        420

    $        322

    $            —

    $                  (2)

    $                324

    $     0.22



    Non-GAAP adjustments:























    Amortization expense

    —

    (213)

    213

    —

    213

    184

    —

    2

    182

    0.12



    Intangible asset impairment charges

    —

    (276)

    276

    —

    276

    243

    —

    —

    243

    0.16



    Acquisition/divestiture-related net

    charges (credits)

    11

    (37)

    48

    1

    49

    38

    —

    —

    38

    0.03



    Restructuring and restructuring-

    related net charges (credits)

    30

    (20)

    50

    —

    50

    44

    —

    —

    44

    0.03



    Investment portfolio net losses (gains)

    and impairments

    —

    —

    —

    31

    31

    29

    —

    —

    29

    0.02



    EU MDR implementation costs

    8

    (4)

    12

    —

    12

    10

    —

    —

    10

    0.01



    Deferred tax expenses (benefits)

    —

    —

    —

    —

    —

    44

    —

    —

    44

    0.03



    Adjusted

    $    2,899

    $      1,780

    $      1,119

    $        (68)

    $      1,051

    $        913

    $            —

    $                  (0)

    $                914

    $     0.62





















































    Three Months Ended June 30, 2023



    (in millions, except per share data)

    Gross

    Profit

    Operating

    Expenses

    Operating

    Income

    (Loss)

    Other

    Income

    (Expense)

    Income

    (Loss)

    Before

    Income

    Taxes

    Net

    Income

    (Loss)

    Preferred

    Stock

    Dividends

    Net Income

    (Loss)

    Attributable to

    Noncontrolling

    Interests

    Net Income

    (Loss)

    Attributable to

    Boston

    Scientific

    Common

    Stockholders

    Impact

    per

    Share(1)



    Reported

    $    2,542

    $      2,028

    $        514

    $        (88)

    $        426

    $        270

    $            (9)

    $                  —

    $                261

    $     0.18



    Non-GAAP adjustments:























    Amortization expense

    —

    (210)

    210

    —

    210

    182

    —

    —

    182

    0.12



    Intangible asset impairment charges

    —

    (57)

    57

    —

    57

    54

    —

    —

    54

    0.04



    Acquisition/divestiture-related net

    charges (credits)

    16

    (106)

    122

    (4)

    118

    175

    —

    —

    175

    0.12



    Restructuring and restructuring-

    related net charges (credits)

    18

    (23)

    42

    —

    42

    35

    —

    —

    35

    0.02



    Investment portfolio net losses (gains)

    and impairments

    —

    —

    —

    (2)

    (2)

    5

    —

    —

    5

    0.00



    EU MDR implementation costs

    14

    (6)

    20

    —

    20

    17

    —

    —

    17

    0.01



    Deferred tax expenses (benefits)

    —

    —

    —

    —

    —

    47

    —

    —

    47

    0.03



    Discrete tax items

    —

    —

    —

    —

    —

    1

    —

    —

    1

    0.00



    Adjusted

    $    2,590

    $      1,626

    $        964

    $        (93)

    $        871

    $        786

    $            (9)

    $                  —

    $                777

    $     0.53



























    (1)For the three months ended June 30, 2023, the effect of assuming the conversion of 5.50% Mandatory Convertible Preferred Stock, Series A (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented within our unaudited consolidated statements of operations, for purposes of calculating net income attributable to Boston Scientific common stockholders.  On June 1, 2023, all outstanding shares of MCPS automatically converted into shares of common stock.





























    An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.



     

    BOSTON SCIENTIFIC CORPORATION

    NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS

    (Unaudited)









    Six Months Ended June 30, 2024



    in millions, except per share data

    Gross

    Profit

    Operating

    Expenses

    Operating

    Income

    (Loss)

    Other

    Income

    (Expense)

    Income

    (Loss)

    Before

    Income

    Taxes

    Net

    Income

    (Loss)

    Preferred

    Stock

    Dividends

    Net Income

    (Loss)

    Attributable to

    Noncontrolling

    Interests

    Net Income

    (Loss)

    Attributable to

    Boston

    Scientific

    Common

    Stockholders

    Impact

    per

    Share



    Reported

    $    5,498

    $      4,303

    $      1,195

    $       (167)

    $      1,028

    $        815

    $            —

    $                  (4)

    $                819

    $     0.55



    Non-GAAP adjustments:























    Amortization expense

    —

    (427)

    427

    —

    427

    369

    —

    4

    364

    0.25



    Intangible asset impairment charges

    —

    (276)

    276

    —

    276

    243

    —

    —

    243

    0.16



    Acquisition/divestiture-related net

    charges (credits)

    22

    (90)

    112

    0

    112

    115

    —

    —

    115

    0.08



    Restructuring and restructuring-

    related net charges (credits)

    55

    (42)

    97

    —

    97

    84

    —

    —

    84

    0.06



    Investment portfolio net losses (gains)

    and impairments

    —

    —

    —

    18

    18

    18

    —

    —

    18

    0.01



    EU MDR implementation costs

    17

    (8)

    26

    —

    26

    22

    —

    —

    22

    0.01



    Deferred tax expenses (benefits)

    —

    —

    —

    —

    —

    81

    —

    —

    81

    0.05



    Adjusted

    $    5,592

    $      3,461

    $      2,131

    $       (148)

    $      1,983

    $     1,746

    $            —

    $                    1

    $              1,745

    $     1.18





















































    Six Months Ended June 30, 2023



    in millions, except per share data

    Gross

    Profit

    Operating

    Expenses

    Operating

    Income

    (Loss)

    Other

    Income

    (Expense)

    Income

    (Loss)

    Before

    Income

    Taxes

    Net

    Income

    (Loss)

    Preferred

    Stock

    Dividends

    Net Income

    (Loss)

    Attributable to

    Noncontrolling

    Interests

    Net Income

    (Loss)

    Attributable to

    Boston

    Scientific

    Common

    Stockholders

    Impact

    per

    Share (2)



    Reported

    $    4,891

    $      3,825

    $      1,066

    $       (195)

    $        870

    $        584

    $          (23)

    $                  —

    $                561

    $     0.39



    Non-GAAP adjustments:























    Amortization expense

    —

    (412)

    412

    —

    412

    357

    —

    —

    357

    0.25



    Intangible asset impairment charges

    —

    (57)

    57

    —

    57

    54

    —

    —

    54

    0.04



    Acquisition/divestiture-related net

    charges (credits)

    27

    (145)

    172

    6

    178

    242

    —

    —

    242

    0.17



    Restructuring and restructuring-

    related net charges (credits)

    35

    (51)

    86

    —

    86

    71

    —

    —

    71

    0.05



    Investment portfolio net losses (gains)

    and impairments

    —

    —

    —

    19

    19

    20

    —

    —

    20

    0.01



    EU MDR implementation costs

    25

    (11)

    36

    —

    36

    31

    —

    —

    31

    0.02



    Deferred tax expenses (benefits)

    —

    —

    —

    —

    —

    88

    —

    —

    88

    0.06



    Discrete tax items

    —

    —

    —

    —

    —

    26

    —

    —

    26

    0.02



    Adjusted

    $   4,978

    $      3,148

    $     1,829

    $       (171)

    $      1,659

    $     1,472

    $         (23)

    $                  —

    $              1,449

    $     1.00



























    (2)For the six months ended June 30, 2023, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income attributable to common stockholders.  On June 1, 2023, all outstanding shares of MCPS automatically converted into shares of common stock.





























    An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.



     

    BOSTON SCIENTIFIC CORPORATION

    Q3 and FY 2024 GUIDANCE RECONCILIATIONS

    (Unaudited)

    Net Sales



    Q3 2024 Estimate



    Full Year 2024 Estimate



    (Low)

    (High)



    (Low)

    (High)

    Reported growth

    13.0 %

    15.0 %



    13.5 %

    14.5 %

    Impact of foreign currency fluctuations

    1.0 %

    1.0 %



    1.0 %

    1.0 %

    Operational growth

    14.0 %

    16.0 %



    14.5 %

    15.5 %

    Impact of acquisitions/divestitures

    (1.0) %

    (1.0) %



    (1.5) %

    (1.5) %

    Organic growth

    13.0 %

    15.0 %



    13.0 %

    14.0 %

    Earnings per Share



    Q3 2024 Estimate



    Full Year 2024 Estimate



    (Low)

    (High)



    (Low)

    (High)

    GAAP results

    $               0.36

    $               0.38



    $               1.34

    $               1.38













    Amortization expense

    0.12

    0.12



    0.48

    0.48

    Intangible asset impairment charges

    —

    —



    0.16

    0.16

    Acquisition/divestiture-related net charges (credits)

    0.03

    0.03



    0.13

    0.13

    Restructuring and restructuring-related net charges

    (credits)

    0.03

    0.03



    0.11

    0.11

    Other adjustments

    0.04

    0.04



    0.16

    0.16

    Adjusted results

    $               0.57

    $               0.59



    $               2.38

    $               2.42

     

    Use of Non-GAAP Financial Measures

    To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share (EPS) that exclude certain charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of acquisitions and divestitures with less than a full period of comparable net sales. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.

    To calculate adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share, we exclude certain charges (credits) from GAAP net income and GAAP net income attributable to Boston Scientific common stockholders, which include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), EU MDR implementation costs, debt extinguishment net charges, deferred tax expenses (benefits) and certain discrete tax items. Amounts are presented after-tax using the company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." Please refer to Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission or Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations in any Quarterly Report on Form 10-Q that we have filed or will file thereafter for an explanation of each of these adjustments and the reasons for excluding each item.

    The GAAP financial measures most directly comparable to adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share are GAAP net income (loss), GAAP net income (loss) attributable to Boston Scientific common stockholders and GAAP net income (loss) per common share – diluted, respectively.

    To calculate operational net sales growth rates, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior periods. To calculate organic net sales growth rates, we also remove the impact of acquisitions and divestitures with less than a full period of comparable net sales. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales reported on a GAAP basis.

    Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules.

    Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments' measures of net sales and profit or loss. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance.

    We believe that presenting adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders, adjusted net income (loss) per share, operational net sales growth rates and organic net sales growth rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results "through the eyes" of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/boston-scientific-announces-results-for-second-quarter-2024-302204682.html

    SOURCE Boston Scientific Corporation

    Get the next $BSX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BSX
    $SILK

    CompanyDatePrice TargetRatingAnalyst
    Boston Scientific Corporation
    $BSX
    6/16/2025$118.00Outperform
    Leerink Partners
    Boston Scientific Corporation
    $BSX
    4/16/2025$113.00Hold → Buy
    Needham
    Boston Scientific Corporation
    $BSX
    1/10/2025$108.00Hold → Buy
    Deutsche Bank
    Boston Scientific Corporation
    $BSX
    10/18/2024Buy → Hold
    Needham
    Silk Road Medical Inc.
    $SILK
    7/11/2024Buy → Sell
    Argus
    Boston Scientific Corporation
    $BSX
    5/30/2024$90.00Buy
    Goldman
    Silk Road Medical Inc.
    $SILK
    3/7/2024$24.00Hold → Buy
    Argus
    Boston Scientific Corporation
    $BSX
    2/1/2024$65.00 → $80.00Neutral → Buy
    Mizuho
    More analyst ratings

    $BSX
    $SILK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & Group Pres, Cardiology Fitzgerald Joseph Michael bought $4,515 worth of shares (50 units at $90.29), sold $1,799 worth of shares (20 units at $89.97), was granted 31,680 shares and covered exercise/tax liability with 14,447 shares, increasing direct ownership by 17% to 172,863 units (SEC Form 4)

      4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

      2/13/25 4:32:41 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Ballinger Kevin J. bought $198,783 worth of shares (11,700 units at $16.99), increasing direct ownership by 192% to 17,807 units (SEC Form 4)

      4 - Silk Road Medical Inc (0001397702) (Issuer)

      3/7/24 6:01:30 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $BSX
    $SILK
    SEC Filings

    See more
    • SEC Form 11-K filed by Boston Scientific Corporation

      11-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

      6/18/25 5:14:10 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific Corporation filed SEC Form 8-K: Other Events

      8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

      5/28/25 7:45:47 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Boston Scientific Corporation

      SD - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

      5/22/25 4:10:21 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    $SILK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by EVP and CFO Monson Jonathan

      4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

      7/2/25 4:09:43 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • EVP & Group Pres, Cardiology Fitzgerald Joseph Michael exercised 50,000 shares at a strike of $26.15 and sold $5,348,315 worth of shares (50,000 units at $106.97) (SEC Form 4)

      4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

      7/2/25 4:09:41 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • SVP, GC and Corp. Secretary Brown Vance R converted options into 4,036 shares and covered exercise/tax liability with 1,952 shares, increasing direct ownership by 7% to 33,451 units (SEC Form 4)

      4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

      7/2/25 4:09:38 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    $SILK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System

      The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use (IFU) labeling for the FARAPULSE™ Pulsed Field Ablation (PFA) System. The updated labeling now includes approval for the system in the treatment of drug refractory, symptomatic persistent atrial fibrillation (AF), an arrythmia in which the heart beats abnormally for at least seven days.

      7/7/25 7:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific announces conference call discussing second quarter 2025 results

      MARLBOROUGH, Mass., July 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2025, on Wednesday, July 23, 2025, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the second quarter on July 23 prior to the conference call. A live webcast and replay for the eve

      7/1/25 8:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Archimedes Vascular Announces Close of Series A Financing led by Sherpa Healthcare Partners and Appoints Raymond W. Cohen as Chairman of its Board of Directors

      BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of

      6/23/25 9:00:00 AM ET
      $BSX
      $KMTS
      Medical/Dental Instruments
      Health Care

    $BSX
    $SILK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Boston Scientific with a new price target

      Leerink Partners initiated coverage of Boston Scientific with a rating of Outperform and set a new price target of $118.00

      6/16/25 7:46:14 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific upgraded by Needham with a new price target

      Needham upgraded Boston Scientific from Hold to Buy and set a new price target of $113.00

      4/16/25 9:01:10 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific upgraded by Deutsche Bank with a new price target

      Deutsche Bank upgraded Boston Scientific from Hold to Buy and set a new price target of $108.00

      1/10/25 8:51:50 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    $SILK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 1, 2024 - FDA Roundup: March 1, 2024

      For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide

      3/1/24 4:00:21 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    $SILK
    Financials

    Live finance-specific insights

    See more
    • Boston Scientific announces conference call discussing second quarter 2025 results

      MARLBOROUGH, Mass., July 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2025, on Wednesday, July 23, 2025, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the second quarter on July 23 prior to the conference call. A live webcast and replay for the eve

      7/1/25 8:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific announces results for first quarter 2025

      MARLBOROUGH, Mass., April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $4.663 billion during the first quarter of 2025, growing 20.9 percent on a reported basis, 22.2 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $674 million or $0.45 per share (EPS), compared to $495 million or $0.33 per share a year ago, and achieved adjusted3 EPS of $0.75 for the period, compared to $0.56 a year ago.

      4/23/25 6:30:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific announces conference call discussing first quarter 2025 results

      MARLBOROUGH, Mass., April 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2025, on Wednesday, April 23, 2025, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the first quarter on April 23 prior to the conference call. A live webcast and replay for the

      4/1/25 8:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    $SILK
    Leadership Updates

    Live Leadership Updates

    See more
    • Archimedes Vascular Announces Close of Series A Financing led by Sherpa Healthcare Partners and Appoints Raymond W. Cohen as Chairman of its Board of Directors

      BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of

      6/23/25 9:00:00 AM ET
      $BSX
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Nalu Medical Appoints Veteran Medtech Executive Raymond W. Cohen Chairman of its Board of Directors

      Nalu Medical, Inc. ("Nalu") announced today the appointment of Raymond W. Cohen to serve as chairman of its board of directors. Raymond Cohen served as the chief executive officer and member of the board of directors of Nasdaq-listed Axonics, Inc., a medical device company he co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1 on the Deloitte Technology Fast 500™ and the Financial Times ranking of the fastest growing companies in the Americas in 2021 and 2022. Cohen retired from Axonics following the November 2024 close of its $3.7 billion sale to Boston Scientific Corporation (NYSE:BSX). Following the sale of Axonics, Cohen was named chairman of the board of Son

      4/3/25 11:00:00 AM ET
      $BSX
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Sherpa Healthcare Partners Appoints Veteran MedTech Executive Raymond W. Cohen as Venture Partner

      BEIJING and IRVINE, Calif., Jan. 6, 2025 /PRNewswire/ -- Sherpa Healthcare Partners, a global healthcare venture capital firm focused on early and growth stage healthcare companies primarily in Asia and the United States, announced today the appointment of Raymond W. Cohen as Venture Partner. Mr. Cohen is a seasoned healthcare executive and until recently, served as the CEO and member of the board of directors of Axonics, Inc., an Irvine, California-based global medical technology company that Cohen co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1

      1/6/25 9:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    $SILK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Silk Road Medical Inc.

      SC 13D/A - Silk Road Medical Inc (0001397702) (Subject)

      9/19/24 8:16:37 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by Silk Road Medical Inc.

      SC 13D - Silk Road Medical Inc (0001397702) (Subject)

      8/12/24 4:21:48 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Silk Road Medical Inc.

      SC 13G/A - Silk Road Medical Inc (0001397702) (Subject)

      7/10/24 1:45:37 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care